The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)
Cancer centers fund small grants to boost morale amid low paylines

Cancer Policy

NIH suspends new embryonic stem cell line submissions

CMS to enter negotiations with drugmakers over the price of four cancer medications

Tens of thousands of healthcare workers strike across the country

FDA delays drug reviews in new voucher program amid safety, efficacy concerns

NIH ends fetal tissue research—again

ACA Marketplace enrollments down by 1.4 million, early data shows

Clinical Roundup

Itismeran autogene + Keytruda demonstrated improvement in recurrence-free survival in neoadjuvant melanoma

Lab-grown organoids reveal how glioblastoma resists treatment

Oral bacterium may promote breast cancer development and spread, Hopkins study finds

UTSW researchers boost the power of CAR T cells to fight cancer

UCLA launches trial comparing two types of PSMA radiopharmaceuticals for recurrent prostate cancer

Most patients support use of AI to help read mammograms with doctor oversight, UTSW survey finds

In The Clinic

Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer

News Analysis
Health Equity
Trials & Tribulations

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account